An open-label, randomized controlled study evaluating the effectiveness of pramipexole extended-release tablets for tardive dystonia. - REDUCTION Trail

Department of Psychiatry, Chiba University Graduate School of Medicine0 个研究点目标入组 24 人开始时间: 2014年9月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) With blepharospasm or oculogyric crisis alone as a symptom of tardive dystonia 2) Without a treatment history with anticholinergic agent 3) Under treatment with clozapine 4) With treatment histroy of deep brain stimulation (DBS) 5) With treatment history of electroconvulsove therapy (ECT) within 3 months prior to the study enrollment 6) With treatment history of botulinum toxin within 3 months prior to the study enrollment 7) Particition history of a clinical trial with any intervention ( i.e., except for observational study), within the most recent 3 months prior to the study enrollment 8) Without notification of a diagnosis of psychiatric disease 9) pregnant or childbearing-potential woman, and woman who are breast-feeding 10) With renal dysfunction: serum creatinine > 2.0 mg/dl 11) With hypersensitivity to any ingredient of the trial drug 12) With a suicide history within the most recent 1 year prior to the study enrollment 13) Assessed as unsuitable for participation in the study by the study physician

发起方

Department of Psychiatry, Chiba University Graduate School of Medicine